- Home
- OBE vs CTNM Comparison
OBE vs CTNM Comparison
Compare OBE & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | OBE | CTNM |
|---|---|---|
| Founded | 1979 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.4M | 550.7M |
| IPO Year | 2005 | 2024 |
Fundamental Metrics
Financial Performance| Metric | OBE | CTNM |
|---|---|---|
| Price | $11.79 | $16.69 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $10.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 633.4K | 527.7K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.21 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.44 | $8.60 |
| 52 Week High | $14.59 | $17.79 |
Technical Indicators
Market Signals| Indicator | OBE | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 60.18 | 61.96 |
| Support Level | $11.55 | $13.65 |
| Resistance Level | $12.48 | N/A |
| Average True Range (ATR) | 0.54 | 0.92 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 76.88 | 87.62 |
Price Performance
Historical ComparisonAbout OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Sale of Oil.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.